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Abstract
Background—Challenges to effective pharmacologic management of symptomatic diabetic 
peripheral neuropathy include the limited effectiveness of available medicines, frequent side 
effects, and the need for ongoing symptom assessment and treatment titration for maximal 
effectiveness. We present here the rationale and implementation challenges of the Diabetes 
Telephone Study, a randomized trial designed to improve medication treatment, titration and 
quality of life among patients with symptomatic diabetic peripheral neuropathy.
Methods—We implemented a pragmatic cluster randomized controlled trial to test the 
effectiveness of an automated interactive voice response tool designed to provide physicians with 
real-time patient-reported data about responses to newly prescribed diabetic peripheral neuropathy 
medicines. 1,830 primary care physicians treating patients in the diabetes registry at Kaiser 
Permanente Northern California were randomized into the intervention or control arm in 
September 2014. Patients assigned to physicians in the intervention group receive three brief 
interactive calls every 2 months after a medication is prescribed to alleviate diabetic peripheral 
neuropathy symptoms. These calls provide patients with the opportunity to report on symptoms, 
side effects, self-titration of medication dose and overall satisfaction with treatment. We plan to 
compare changes in self-reported quality of life between the intervention group and patients in the 
control group who receive three non-interactive automated educational phone calls.
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Results—Successful implementation of this clinical trial required robust stakeholder engagement 
to help tailor the intervention and to address pragmatic concerns such as provider time constraints. 
As of October 27, 2015, we had screened 2,078 patients, 1,447 of whom were eligible for 
participation. We consented and enrolled 1,206 or 83% of those eligible. Among those enrolled, 
53% are women and the mean age is 67 (sd 12). The racial ethnic make-up is 56% white, 8% 
Asian, 13% black or African American, and 19% Hispanic or Latino.
Conclusions—Innovative strategies are needed to guide improvements in healthcare delivery 
for patients with symptomatic diabetic peripheral neuropathy. This trial aims to assess whether 
real-time collection and clinical feedback of patient treatment experiences can reduce patient 
symptom burden. Implementation of a clinical trial closely involving clinical care required 
researchers to partner with clinicians. If successful, this intervention provides a critical 
information feedback loop that would optimize diabetic peripheral neuropathy medication titration 
through widely available interactive voice response technology.
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Introduction
Diabetic peripheral neuropathy is a painful and prevalent complication that affects over 5.5 
million people with diabetes, including up to 50% of diabetes patients with longstanding 
disease.1 Diabetic peripheral neuropathy is characterized by pain, burning, pins and needles 
sensations, and/or numbness in the toes and feet.2 Symptoms related to diabetic peripheral 
neuropathy are associated with lower quality of life, limited mobility, depression, and social 
dysfunction.3,4
A major challenge to effective treatment of diabetic peripheral neuropathy symptoms is the 
lack of strong clinical evidence to guide which treatments are likely to work for individual 
patients. There are currently a wide range of available medications to treat diabetic 
peripheral neuropathy symptoms including tricyclic antidepressants, anticonvulsants, 
serotonin norepinephrine reuptake inhibitors, and opioid analgesics.2,5,6 First line therapies 
require intensive step-wise titration to reach a dose that optimally balances symptom relief 
with side effect burden. Ultimately, many of these treatments relieve only 20 to 30% of pain 
symptoms. Moreover, all available treatments have significant side effects such as dizziness, 
somnolence, nausea and confusion that may be intolerable to some patients.2,5-8 Given the 
complexity of diabetic peripheral neuropathy medication management, new tools are needed 
to support more effective prescription and titration of available medicines.
For conditions like diabetic peripheral neuropathy, where there is a high degree of individual 
patient variability in treatment tolerance and efficacy, physicians must rely more extensively 
on patient preferences and experiences to inform symptom management.9 Research suggests 
that facilitating timely communication and information exchange between patients and 
physicians can contribute to patient satisfaction with treatment decisions and improve 
quality of life.10
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We designed a study to implement and evaluate a new care tool that uses an automated 
interactive voice response system to extend the window of opportunity for more effective 
patient-provider communication. This interactive voice response system gathers patient 
responses to help guide physicians in timely dose titration and medication changes. Our 
primary research goal is to facilitate more effective medication titration by collecting and 
transferring patient responses about new medication to the physician's electronic health 
record. We hypothesize that this technology-enabled communication feedback tool will 
improve patient quality of life by promoting clinically appropriate treatment changes. The 
purpose of this article is to describe the study protocol and the specific challenges we 
addressed in implementing this pragmatic trial.
Methods
Study setting
Kaiser Permanente Northern California is an integrated health care system serving more 
than 3.6 million people in California, including more than 260,000 members with diabetes 
who are automatically enrolled in the Kaiser Permanente Northern California diabetes 
registry.11
Usual care for patients with diabetes and related chronic conditions in this setting includes a 
robust panel management approach that leverages performance feedback, system-wide 
efficiencies, disease registries and evidence-based practice.12 The electronic medical record 
at Kaiser Permanente Northern California is a critical component of this comprehensive 
disease management strategy.13,14
Stakeholder engagement strategy
Given the pragmatic nature of this trial, we engaged patients with diabetic peripheral 
neuropathy and clinical stakeholders in all aspects of the research from the identification of 
the research question to the design of the intervention and dissemination of research 
findings. Our stakeholder panel includes three patients, three primary care physicians (one 
of whom is an expert in electronic medical record physician prompts), one nurse case 
manager, two pharmacists, one health educator, and one endocrinologist. Our approach to 
stakeholder engagement is grounded in a framework developed by one of the authors 
(Schmittdiel) on system-based participatory research in health care.15 The four principles 
guiding our efforts are: 1) partnership and collaboration in all phases of research; 2) building 
upon existing resources and goals, 3) creating and investing in long term robust partnerships 
and 4) engaging in research as a cyclical and iterative process.15
Physician-level randomization, participant eligibility, and consent
We randomized at the physician level to reduce the likelihood of contamination among 
patients seen by the same physician. One thousand eight hundred and thirty four Kaiser 
Permanente Northern California primary care physicians with adult patients in the Kaiser 
Permanente Northern California diabetes registry were randomized to the intervention or 
control group prior to patient eligibility determination and recruitment using a 
randomization procedure available in the SAS® software package.16 Of those randomized, 
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1,714 physicians had patients who met the initial inclusion and exclusion criteria. In October 
2014, we notified these physicians that their patients may be eligible for a new clinical trial, 
explained the trial, and invited them to opt out any patient due to illness or other factors that 
would make them ineligible for participation. Among diabetes patients not opted out by their 
physicians, we use the electronic health record to prospectively identify patients who start a 
new prescription (i.e., no use in the previous 12 months) for medications commonly used to 
treat diabetic peripheral neuropathy symptoms (amitriptyline, nortriptyline, imipramine, 
desipramine, duloxetine, paroxetine, citalopram, pregabalin, venlafaxine, or gabapentin) 
between September 2014-November 2015 and who have screened positive for diabetic 
peripheral neuropathy symptoms at least once during a routine visit occurring between April 
2012 (when the screener was implemented system-wide) and the time they started 
medication.
Research associates send recruitment letters describing the study and potential risks and 
benefits of participation. The materials sent to patients in the treatment and control arms 
were identical. Patients are contacted by an interviewer by phone one week later to obtain 
phone consent and to conduct the baseline interview. To reduce the risk of selection bias, 
research associates and interviewers are blinded to treatment assignment from consent 
through outcomes assessment. Patients are blinded to their treatment status at the time of 
recruitment. The procedures followed are in accordance with the ethical standards of the 
responsible committee on human experimentation, the Kaiser Permanente Internal Review 
Board, which has reviewed and approved the study protocol. The study is registered at 
ClinicalTrials.gov (CE-1304-7250).
To be eligible for inclusion, identified patients have to be 18 years old at the time they start 
therapy, be continuously enrolled in Kaiser Permanente Northern California during the 12 
months prior to starting study medications, and speak English or Spanish. We exclude 
patients who have a diagnosis of gestational diabetes, dementia or substance abuse disorder 
during the previous 12 months or who have any opioid use during the 90 days prior to 
starting diabetic peripheral neuropathy treatment. (Figure 1)
As we identify potential participants, study telephone interviewers confirm that they have 
active diabetic peripheral neuropathy symptoms and that the prescribed study medications 
are for diabetic peripheral neuropathy and not some other condition. In addition, the 
interviewers identify other factors that may impede participation in this telephone based 
study such as undiagnosed cognitive deficits or use of rotary phones.
The Intervention
Patients of physicians allocated to the intervention arm receive all usual care for diabetes 
and diabetic peripheral neuropathy, plus three five-minute interactive voice response calls 
spaced two months apart over the six-month period following start of diabetic peripheral 
neuropathy treatment. These interactive calls systematically collect patient information on 
symptom relief, medication use, titration, discontinuation and side effects. Patient responses 
are then manually entered into the electronic health record by a trained research assistant. 
Responses indicating dissatisfaction with the level of symptom relief, side effects, and/or 
discontinuation of (or failing to start) the medication are forwarded directly to the physician 
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for more rapid physician notification and response. Responses from patients who report no 
major problems with their diabetic peripheral neuropathy medication are entered into the 
health record but not forwarded to the physician since no immediate follow-up is required. 
(Table 1)
Control arm
Patients of physicians allocated to the control arm receive all usual care for diabetes and 
diabetic peripheral neuropathy, plus three non-interactive, automated telephone calls spaced 
two months apart over the six months following start of a diabetic peripheral neuropathy 
treatment. The automated telephone calls consist of three separate diabetes-related 
educational messages about physical activity, dietary changes, and the importance of regular 
foot checks and last about two minutes or less. The goal of providing these non-interactive 
calls is to isolate the marginal impact of receiving an automated, diabetes-related phone call 
in the intervention arm. Intervention and control calls are offered in English and Spanish.
Outcome measures
The primary outcome measure is quality of life as measured by the Global Health Scale, a 
10-item PROMIS® measure developed and validated in patients with neuropathy as part of 
the Quality of Life in Neurological Disorders Measures.16 The questionnaire includes 
questions about quality of life, mood, physical and social functioning and pain severity. Data 
are collected by trained researchers during 20-minute computer assisted telephone 
interviews at approximately 30 days before the first and 30 days after the final interactive 
voice response/control call. (Table 2)
To assess the mechanisms by which the intervention may impact quality of life, we are also 
capturing the following secondary outcome measures using instruments from the Quality of 
Life in Neurological Disorders Measures: Pain Interference, Sleep Disturbance, Depression, 
Ability to Participate, and Lower Extremity Functioning.17 In addition, we will evaluate 
patient-perceived changes in communication between patients and their doctors using the 
six-item Doctor Communication Composite from the Consumer Assessment of Health Plans 
Survey. This instrument is used routinely in this setting and refers to the patient's most 
recent visit.18 Using the electronic health record, we will also assess changes in medication 
use and physician prescribing patterns.
Evaluation of the intervention's effectiveness
We will evaluate the intention-to-treat effect of the interactive voice response intervention 
compared to the control intervention on the change in quality of life measurements collected 
at baseline and 30 days after the final interactive voice response/control call using 
generalized estimating equations to account for repeated (patient) measures within physician 
clusters.19,20 Double robust estimation will be implemented in secondary analyses to address 
any observed imbalance in characteristics between the control and intervention groups at 
baseline21 and to address any evidence of differential rates of missing outcomes due to 
dropout between the two arms.22-24 Generalized estimating equations analyses will be 
conducted using the GENMOD procedure in SAS® for fitting a linear model with repeated 
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measurements. Doubly robust estimation will be conducted using the ltmle R package 
(available at: https://cran.r-project.org/web/packages/ltmle/index.html).
Our protocol includes testing for heterogeneity in study outcomes by patient desire for 
shared decision making. However, the high response rate will enable for additional 
secondary analyses of physician characteristics such as age, gender, and years at Kaiser 
Permanente Northern California, as well as patient's perception of physician communication 
skills, as potential moderators of intervention effects.
Sample size and power considerations
Estimating the minimum detectable effect was challenging in this prospective pragmatic trial 
because we could not know in advance how many patients would become eligible during the 
enrollment period. Based on our prior studies, we estimated that 118 patients would be 
newly started on diabetic peripheral neuropathy treatment each month (est. n=2,124 over 18 
months) and that, on average, most physicians would have one patient enrolled only. 
Assuming 1,062 patients are approached to participate in each arm, that none of these 
patients share the same primary care physician, a 40% participation rate and 20% loss to 
follow-up (complete data for 340/arm), the minimum detectable mean score difference 
between the two groups with alpha=0.05, beta=0.2, and an outcome with standard deviation 
of 0.143 is 0.030.25-27 Previous studies have estimated a minimally meaningful difference in 
the quality of life measure to be 0.074,28 indicating that we should be able to evaluate 
clinically meaningful changes in quality of life. To ensure our ability to conduct secondary 
analyses, we set a target enrollment of 1,190 patients or 595 per arm.
Given an average cluster size of 1.5 patients per physician and a commonly assumed 
intraclass correlation coefficient of 0.05, accounting for clustering would amount to a 
negligible variance inflation factor of 1.025, resulting in a minimum detectable effect of 
0.0305 (which also results in an increase of 17 patients for a total of 697 patients with 
complete data required for detecting an effect of 0.030). Given that we have already 
collected baseline data on more than 1,200 patients and have a drop-out rate of less than 2%, 




Recruitment of patients began in October 2014, approximately four months later than 
initially planned. However, the rate of new medication starts has been higher than 
anticipated. By October 27, 2015, we had screened 2,078 patients, 1,447 of whom were 
eligible for participation. Among those eligible, 877 unique primary care physicians were 
represented. The most common reasons for ineligibility were use of study medications for 
conditions other than diabetic peripheral neuropathy, absence of active symptoms, and lack 
of proficiency in Spanish or English language. We consented and enrolled 1,206 or 83% of 
those eligible, representing 792 unique primary care physicians and 54 facilities. 
Recruitment rates are similar across the two arms (control=82.7%; treatment=83.9%). 
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Common reasons for refusal included lack of interest in participating in a study, being too 
sick to participate and being too busy.
Since the start of recruitment, twenty patients (<2%) have dropped out of the study. The 
most common reasons for drop out were worsening health status, caregiving responsibilities 
and challenges with the interactive voice response system such as missed calls.
Characteristics of enrolled subjects
Among the 1,206 enrolled as of October 27, 2015, 53% are women and the mean age is 67 
(standard deviation: 12). The racial ethnic make-up is 56% white, 8% Asian, 13% black or 
African American, 19% Hispanic or Latino, 1% Native Hawaiian, Pacific Islander, or Native 
American, and 1% unknown. We have collected baseline data on 1,191 patients, 71 of 
whom conducted the survey in Spanish. Close out surveys have been completed by 92% 
(589) of those who have completed the intervention. We identified no statistically significant 
differences in the demographic characteristics or in baseline quality of life between the 
treatment and control arms. (Table 3)
Changes to the initial study plan based on stakeholder feedback
This pragmatic, cluster randomized study is designed to be maximally generalizable to the 
patients and clinical settings in which the intervention is being tested.29 However, the 
pragmatic nature of the study design also presented several challenges that were addressed 
through collaboration with patient and provider stakeholders:
1. Isolating the impact of the intervention. While we use the interactive voice 
response as a mechanism for facilitating the feedback tool, we wanted to measure 
the impact of the feedback tool, not the receipt of an automated call. The creation 
of non-interactive automated educational calls for the control group ensures that 
any differences between the groups will be related to the feedback tool. 
Stakeholders helped to choose the content of these automated calls.
2. Avoiding physician information overload. Our clinician stakeholders emphasized 
the need to limit the data being forwarded to clinicians to clinically “actionable” 
information (e.g., information that would trigger changes in dose or medication 
class). Our triage system prioritizes patients for more rapid intervention if they 
report being dissatisfied with the level of symptom relief, are experiencing side 
effects, or are discontinuing medication. These triggers for action were selected by 
our clinician stakeholders.
3. Tailoring the intervention to patient population. Our patient population includes a 
disproportionate number of frail and disabled people, patients who are frequently 
excluded from traditional clinical trials. As a consequence, we found early on that 
some patients were having difficulty reaching the phone in time to receive the 
interactive voice response calls and interacting with the interactive voice response 
system. To address these issues, the interviewers now provide patients with a toll 
free number to call into the system should they miss a call. In addition, we 
increased the number of interactive voice response call attempts from 3 to 8 to 
maximize participation among all patients.
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This study tests the potential for an interactive voice response-based feedback intervention 
to improve quality of life for patients newly treated for diabetic peripheral neuropathy 
symptoms. While there is no cure for diabetic peripheral neuropathy, symptoms are treatable 
and ameliorable through medications and frequent monitoring of patient symptoms and side 
effects to facilitate clinically appropriate treatment changes for maximum benefit.5-8 
Unfortunately, many patients may never achieve the maximum benefit from their 
medications due to the absence of routine monitoring of symptoms and treatment effects.2,3
In this study, we use a cluster randomized trial design, endeavoring to reduce common 
threats to validity,30 in order to evaluate the impact of an intervention to address this gap in 
care. As with any study, this approach has some limitations that deserve consideration. First, 
we chose to randomize at the physician level to reduce risk of contamination among patients 
treated by the same physician. However, the possibility of contamination among physicians 
in the same medical center remains. We estimate the risk of such contamination to be 
minimal due to the small number of patients affected over a long period of time and the 
absence of any changes in clinical workflows.
In addition, we randomized physicians to either the treatment or control condition prior to 
consenting patients to reduce the possibility of selection. However, this decision means that 
we have some attrition of physicians post randomization, as well as some physicians with no 
eligible patients. In addition, while patients are blinded to treatment assignment at the time 
they consent, it is possible that patients in the intervention may correctly guess their status 
due to the interactive nature of the intervention phone calls. Therefore, we will compare the 
characteristics of physicians and patients who drop out to assess whether they differ in 
systematic ways from those included in the study. However, our very low drop-out rates 
suggests that threats to validity related to this type of bias should be minimal.
Leveraging available technology to supplement patient-provider communication about 
symptoms has the potential to facilitate treatment titration and to improve patient treatment 
experiences and quality of life. If successful, the methods employed in the Diabetes 
Telephone Study trial could apply to other conditions where timely feedback of information 
on treatment efficacy and side effects are critical to achieving optimal outcomes.
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Figure I. Timeline for Study Recruitment and Follow-up
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Table 1
Content of Data Collected from Interactive Voice Response Calls in Intervention Group
Call 1 Calls 2 and 3
Patient still taking the medication prescribed for diabetic 
peripheral neuropathy
Overall diabetic peripheral neuropathy symptom status
Reason(s) if patient no longer taking medication: Patient still taking the medication prescribed for diabetic peripheral neuropathy
Medication not helpful for symptoms Reason(s) if patient no longer taking medication:
Told by physician to stop the medication Medication not helpful for symptoms
Symptoms got better Told by physician to stop the medication
Taking too many medications, didn't want to add another Symptoms got better
Side effects Taking too many medications, didn't want to add another
Medication costs too much Side effects
Other reasons Medication costs too much
Patient usually takes medication daily Switched medications
Patient decided to increase or decrease medication dosage Other reasons
How well medication working to reduce symptoms Patient started diabetic peripheral neuropathy medication in last two months
Medication working as well as patient hoped In the last two months, patient decided to increase or decrease medication 
dosage
Diabetic peripheral neuropathy medication side effects in 
last 7 days
Patient taking more than one medication for diabetic peripheral neuropathy 
symptoms
Medication working as well as patient hoped
Diabetic peripheral neuropathy medication side effects in last 7 days
Patient considered stopping diabetic peripheral neuropathy medication because 
of side effects
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Table 2
Schedule of Data Collection
Type Instrument Domain Baseline Follow Up
Primary Outcomes Global Health Scale Overall health status Yes Yes
Secondary Pain Interference Pain Yes* Yes
Sleep Disturbance Sleep Yes Yes
Depression Depression Yes* Yes
Ability to Participate Social Functioning Yes* Yes
Lower Extremity Functioning Physical Functioning Yes* Yes
6 Item Doctor Communication Composite (CAHPS) Communication Yes Yes
Potential Effect Modifiers SDM-Q-9 Shared decision making Yes No
Adaptive Conjoint Analysis Tool Treatment Preferences Yes** No
*
Restricted to patients who indicated difficulty in that domain on the global health scale.
**
To be administered to a subset (∼200) of patients.













Adams et al. Page 14
Table 3
Characteristics of Patients Enrolled in the Diabetes Telephone Study as of October 27, 
2015
N (%) All (N=1,191) Control Group (N=623) Treatment Group (N=568) P value*
Gender 0.6245
 Female 637 (53.5) 329 (52.8) 308 (54.2)
 Male 554 (46.5) 294 (47.2) 260 (45.8)
Race/Ethnicity 0.5476
 White 672 (56.4) 350 (56.2) 322 (56.7)
 Asian 98 (8.2) 45 (7.2) 53 (9.4)
 Black 161 (13.5) 87 (14.0) 74 (13.0)
 Hispanic 232 (19.5) 124 (19.9) 108 (19.0)
 HI/PI/NA 14 (1.2) 10 (1.6) 4 (0.7)
 Unknown 14 (1.2) 7 (1.1) 7 (1.2)
Spanish Speaker 0.9728
 Yes 71 (6.0) 37 (5.9) 34 (6.0)
 No 1,120 (94.0) 586 (94.1) 534 (94.0)
Age Mean ± Standard Deviation 67.1 ± 11.8 67.1 ± 11.5 67.2 ± 12.0 0.8355
Quality of Life (EQ5D) Mean ± Standard 
Deviation
0.65 ± 0.1 0.65 ± 0.1 0.66 ± 0.1 0.4538
*
comparing control and treatment
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